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Background: Subclinical thyroid dysfunction, characterized by abnormal serum 
thyrotrophin (thyroid stimulating hormone [TSH]) concentrations with normal free 
thyroxine (FT4), is common in the elderly. Whether individuals with subclinical serum 
status experience an increased symptom profile remains unclear. 
Aim: To compare the prevalence of those symptoms typically associated with overt 
thyroid dysfunction in older individuals with a subclinical and euthyroid serum profile.  
Design and setting: Cross-sectional, nested within the Birmingham Elderly Thyroid 
Study (BETS), 19 general practices, UK.  
Method: Community dwelling adults (aged 65 years), without overt thyroid dysfunction 
or associated treatment, self-reported presence or absence of 18 symptoms (whilst 
serum result naïve). Serum concentrations of TSH and FT4 were measured to establish 
thyroid status. 
Results: 2870 individuals were screened, 2703 (94%) were categorized as euthyroid 
(normal), 29 (1%) subclinically hyperthyroid and 138 (5%); subclinically hypothyroid. 
Weight gain was reported by 54% (CI; 45.3-61.7%) and fast thinking by 31% (CI; 17.3-
49.2) of individuals with subclinical hypo- and hyperthyroidism respectively. No 
significant differences in the prevalence of individual symptoms were observed between 
the euthyroid and subclinical hypothyroid groups nor in comparison with the subclinically 
hyperthyroid group. Multivariate logistic regression analysis failed to reveal an 
association between individual or multiple symptoms and subclinical status.   
Conclusion: Findings suggest that subclinical thyroid dysfunction does not confer a 
symptom burden in older individuals and support adherence to guidelines in the non-
treatment of subclinical thyroid dysfunction. GPs may use the findings to reassure older 
people presenting with symptoms that subclinical thyroid dysfunction is an unlikely 
explanation. The presence of persistently abnormal TSH concentrations may be linked to 
long-term risks of cardiovascular disease, especially Atrial Fibrillation, but whether this 




How this fits in 
Subclinical thyroid dysfunction is a biochemical diagnosis that is common in older age.  
Although older patients with this diagnosis may report symptoms like those found in 
overt thyroid dysfunction, it is unknown whether subclinical thyroid dysfunction itself is 
associated with symptom excess. This large population-based survey demonstrates that 
subclinical thyroid dysfunction in the older population does not confer additional 
symptom burden. Findings support current guidance for not treating subclinical thyroid 
dysfunction in older individuals and provide an evidence base for GPs to use in 
discussion with patients experiencing symptoms who have mildly abnormal thyroid 




Introduction   
Subclinical thyroid dysfunction is characterised by TSH concentrations outside the stated 
reference range accompanied by FT4 concentrations within the reference range. (1) 
Thyroid function tests are commonly requested for older adults in primary care either 
routinely or in response to presentation of symptoms and identify large numbers of 
individuals with subclinical thyroid dysfunction. (2-6)  
 
We have previously demonstrated low levels of progression (<0.5%) of subclinical 
thyroid dysfunction to overt disease in older individuals over a period of up to 5 years, 
supporting guidelines that indicate treatment of subclinical dysfunction is not necessary 
to prevent progression.(7) However, a better understanding of whether subclinical 
thyroid dysfunction itself is associated with any symptom excess which may be 
amenable to intervention is still required to guide clinical management of this condition. 
 
A previous community-based population study demonstrated symptoms to be poorly 
predictive of TSH, (8) although other research suggests a higher prevalence of 
symptoms in individuals with subclinical thyroid dysfunction. (9-11) These studies 
however have significant limitations in their application to primary care or community-
based populations being derived from endocrine clinic populations. (9-11). Additionally, 
these data relate to middle aged populations (all studies have mean ages in the range 
43-47 years), where the overlap of symptoms attributable to older age and thyroid 
dysfunction are likely to be less widespread and hence more discriminatory.  
 
Therefore there continue to be calls for further research in subclinical thyroid dysfunction 
due to the poor understanding of how to best manage this condition. (12,13) This study 
aimed to build on previous work and definitively explore whether subclinical thyroid 
dysfunction in older adults confers additional symptom burden and also whether specific 
symptom clusters are associated with subclinical thyroid dysfunction rather than being 
typical of older age presentations. Such understanding may enable reductions in the 








Recruitment and participants 
This cross-sectional survey was nested within a longitudinal study of thyroid function in 
an established cohort (the Birmingham Elderly Thyroid Study (BETS) cohort) of 5881 
community dwelling individuals from 19 practices 
representative of the UK. (3,7,14-15). GPs confirmed eligibility and suitability of follow-up 
for participants of the original BETS cohort as previously reported.(7) Individuals were 
excluded if they were no longer registered with the practice, were deceased, had a 
diagnosis of overt thyroid dysfunction, had received treatment for thyroid dysfunction or 
were judged to be inappropriate for contact (e.g. recently bereaved or terminally ill). 
 
Eligible participants received a postal invitation letter, reply slip and free post envelope 
addressed to the research office. Patients interested in participating were sent a 
symptoms questionnaire with a request to complete it prior to attending the research 
clinic for venepuncture. At the clinic, consent was obtained and a blood sample for 
thyroid function testing acquired. Samples were collected in plastic vacuette 4ml serum 
separator clot activator tubes. Research clinics were conducted over a period of 19 
months with symptom details being provided concurrent to individual patient 
appointments.   
 
Evaluation of symptoms  
Participants self-reported the presence or absence of 18 classic symptoms of overt 
hypo- and hyperthyroidism by questionnaire. The questionnaire was a supplemented 
version of the Colorado Hypothyroid Symptom survey, a validated questionnaire for  
assessment of symptoms of thyroid hormone deficiency. (16-17). The format of the 
original survey was preserved; however, six hyperthyroid symptoms identified from the 
literature were added. (18-19). The final questionnaire comprised: six hyperthyroid 
symptoms (weight loss, fast thinking, frequent palpitation, sensitivity to heat, tremor and 
excessive perspiration), nine hypothyroid symptoms (hoarse voice, deep tone of voice, 
dry skin, puffy eyes, muscle cramps, constipation, slow thinking, sensitivity to cold and 
weight gain) and three symptoms (poor memory, lethargy and weak muscles) which can 
be associated with both hyper- and hypothyroidism.  
 
The questionnaire was piloted by 10 volunteers aged 65 years to assess user 
understanding and experience. Refinements were made based upon the feedback 
obtained.  
 
Thyroid function testing  
Thyroid function testing was performed by the Regional Endocrine Laboratory at the 
University Hospital Birmingham, National Health Service Foundation Trust (UHB). Serum 
TSH and FT4 concentrations were determined for all individuals. If a serum TSH 
concentration above or below the limits of the reference range was identified, serum free 
tri-iodothyronine (FT3) was also measured. Serum TSH, FT4, and FT3 concentrations 
were measured by electrochemiluminescent immunoassays using the Roche E170 
(Roche Diagnostics, Burgess Hill, UK). The TSH assay was calibrated against the 
second international reference preparation 80/558. The associated inter-assay 
coefficient of variation for TSH was 1.5% (0.5-33.0 mlU/L), FT4 2.0-2.5% (9.0-66.0 
pmol/L) and FT3 2.0-3.5% (4.0-21.0 pmol/L). The lower limit of reporting for the TSH 
an functional sensitivity was 
0.014 mIU/L. Algorithms relating to current local clinical practice and laboratory 





Table 1. Classification of thyroid status based upon TSH and FT4 concentration  
 
Demographic and lifestyle data 
Age and deprivation score were calculated from the participants
postcode, respectively. The Index of multiple deprivation 2004 (IMD) was used as a 
proxy measure of socioeconomic status with higher IMD scores indicating greater 
deprivation. (20) Primary care medical records were reviewed to collect data on medical 
history and concomitant prescription medication pre-specified as likely to be associated 
with category of thyroid function, with reported symptoms or to interfere with tests of 
thyroid function. Participants self-reported smoking status.  
 
Statistical analysis  
T tests and chi squared tests were used to compare the participants with subclinical 
hypo- and hyperthyroidism with euthyroid participants with respect to patient 
characteristics (e.g demographics, medical history, concomitant disease and prescription 
medication). Univariate logistic regression techniques were used to establish unadjusted 
odds ratios representing the odds of subclinical hypo- or hyperthyroidism in subjects 
reporting presence of individual symptoms divided by the odds of subclinical hypo-or 
hyperthyroidism in subjects reporting absence of the symptom.  
 
Multivariate logistic regression analysis was then undertaken to further examine the 
relationship between individual symptoms and thyroid function category and establish 
the likelihood of subclinical thyroid dysfunction after controlling for the effects of the 
covariates; age, gender, deprivation score, smoking status, concomitant disease and 
prescription medication. To enable further exploration of the relationship between 
category of thyroid function and presence of multiple symptoms, uni- and multivariate 
logistic regression was undertaken to establish the change in odds of a subclinical hypo-
or hyperthyroid result as the total number of symptoms reported increased, with and 






Four thousand four hundred and forty-seven individuals were invited to participate in the 
follow-up screening study (Figure 1). Participants were excluded from the original cohort 
(n=5881) if during the 5-year interval period they had died (n=501), deregistered from 
participating practice (n=453), or become unsuitable for contact, as judged by the 
responsible general practitioner (n=381). Individuals who had been diagnosed with or 
received treatment for thyroid dysfunction were also excluded (n=99). Overall, 66% 
(2936/4447) of those invited attended a research clinic and consented to participate. In 
total, 2870 (65%) were fully screened and included in the analysis. Reasons for 
exclusion from the analysis were missing TFT results or missing symptom data (n=13) 
and newly identified treatment for thyroid dysfunction (n=53).  
 
Description of the subgroups 
A total of 2703 participants (94%, n=2870) were classified as euthyroid, 138 (5%) as 
subclinically hypothyroid and 29 (1%) subclinically hyperthyroid. The euthyroid group 
were slightly younger than the subclinically hyperthyroid group (mean age 76.8 versus 
79.1 years respectively, p=0.02) and the subclinically hypothyroid group (mean age 76.8 
versus 77.7 years respectively, p=0.05). The three groups were similar with respect to 
gender and deprivation score. A significantly higher proportion of the euthyroid group 
compared with the subclinically hypothyroid group had a previous diagnosis of 
pulmonary disease (12.9% versus 3.6%, p=0.03) but there were no statistically 
significant differences between the euthyroid and subclinical groups with respect to any 
other concomitant disease or prescription medication. (data not shown).  
 
Symptom expression and subclinical hypothyroidism  
There were no significant differences between the euthyroid and subclinical hypothyroid 
groups with respect to presence of individual or multiple hypothyroid symptoms (Table 
2). Unadjusted and adjusted odds ratios representing the odds of subclinically 
hypothyroid status in subjects reporting symptom presence divided by the odds of 
subclinical status in subjects reporting symptom absence are reported. Visual 
exploration of the distribution of total number of symptoms reported by the euthyroid and 
subclinical hypothyroid groups did not demonstrate a clear relationship between multiple 
symptoms and thyroid function category (Figure 2).  
 
Symptom expression and subclinical hyperthyroidism  
For completeness we report in Table 3 the prevalence of individual symptoms and total 
number of symptoms reported in the euthyroid and subclinical hyperthyroid groups, 
although acknowledge that a low number of identified subclinically hyperthyroid cases 
restricts interpretation. No significant differences between the groups were observed with 
respect to presence of any individual hyperthyroid symptom or total number of symptoms 
reported. Visual exploration of the distribution of total number of symptoms reported by 
the groups also failed to demonstrate a clear relationship between total number of 









This population survey suggests that symptoms commonly associated with overt thyroid 
dysfunction are relatively prevalent in older community dwelling individuals. This study 
did not however demonstrate a greater prevalence of any established symptoms in those 
with subclinical thyroid dysfunction compared to euthyroid controls. Furthermore, 
presence of multiple symptoms were not associated with subclinical thyroid dysfunction.  
 
Strengths and limitation 
The strengths of this study are the large number of unselected older individuals 
investigated and the simultaneous and detailed evaluation of thyroid function, self-
reported symptoms, concomitant disease and prescription medication. Evidence based 
development of the symptoms questionnaire was employed to ensure that the most 
relevant and sensitive symptoms, reflecting a variety of metabolic processes and 
involving a range of organ systems, were selected and captured. Furthermore, all 
participants completed the questionnaire prior to thyroid function testing so that their 
responses were not influenced by knowledge of their thyroid status.  
 
This study did not evaluate other clinical effects, such as altered cardiac morphology, 
that may be attributed to subclinical thyroid dysfunction. Further evidence in such 
impacts is needed in relation to unselected populations to fully determine any 
consequence of living with marginally altered TSH or FT4.  
     
Comparison with existing literature  
This study failed to identify symptoms which alone or in combination are associated with 
subclinical thyroid dysfunction in older individuals. This contrasts with previous studies 
(9-11) which identified an increased symptom burden, but whose findings are likely to be 
influenced by the recruitment from a secondary care endocrine settings and smaller 
cohorts. 
 
It is also noted that direct comparison with these studies is not supported by the much 
younger populations recruited, with this being the first significant screening study to 
explore symptom profiles in an older cohort, ie the general population who are most 
likely to receive thyroid function testing and be identified with sub-clinical thyroid states.  
 
These findings support those of a smaller retrospective case-note study conducted in a 
primary care geriatric service which found no significant difference in the frequencies of 
any signs or symptoms associated with hypothyroidism between subclinical and 
euthyroid individuals. (21).  
 
Implications for practice and research  
Overall findings suggest that subclinical thyroid dysfunction does not confer a symptom 
burden in older community dwelling individuals. This lack of association further supports 
adherence to guidelines in the non-treatment of subclinical thyroid dysfunction and 
provides an evidence base for GPs to use in discussion of symptoms and associated 
likelihood of subclinical dysfunction explaining these in their older patients.  
 
In older individuals the diagnosis of subclinical thyroid dysfunction should be based upon 




exclude acute non-thyroidal and drug related causes) abnormal TSH levels alongside 
FT4 levels within reference range. (22) 
 
In terms of management of subclinical thyroid dysfunction, the findings of a recent meta-
analysis and systematic review incorporating data from 21 trials do not support the 
routine use of thyroid hormone therapy in adults with subclinical hypothyroidism. Results 
of this review consistently demonstrated no association of therapy with improved 
outcomes. (23) 
 
The evidence to guide management of subclinical hyperthyroidism remains inconclusive 
with few interventional studies showing benefit in clinically important outcomes. Since 
epidemiological data demonstrate an increased rate of atrial fibrillation, heart failure and 
coronary heart disease with subclinical hyperthyroidism, current European Thyroid 
Association guidelines recommend that treatment of subclinical hyperthyroidism be 
considered in older patients with cardiovascular disease, diabetes and renal failure to 
avoid longer-term risks. (15,24,25) NICE guidelines on the assessment and 
management of thyroid disease are in development and are scheduled for publication 
November 2019. (26) Considering this evidence, in the presence of persistently low 
levels of TSH (especially levels <0.1mIU/) alongside pre-existing cardiovascular disease 
and increased cardiovascular risk factors, GPs may want to discuss with their patients 
the possible long-term risks of subclinical hyperthyroidism in order to determine whether 
to intervene or abstain from treatment. Such discussions will however be limited by 
uncertainty whether this association is clinically significant and the lack of any evidence 
on the effectiveness of treatment for reducing any risks associated with subclinical 
hyperthyroidism. Treatment of all grades of hyperthyroidism should most appropriately 
be instituted by endocrine specialists.(27) 
 
Further large-scale, longitudinal research is required to establish the clinical significance 
of the etiolgy of subclinical hyperthyroidism and the impact of treatment on 






Figure 1. Study flow diagram 
 
Figure 2. Total number of hypothyroid symptoms reported by the euthyroid and 
subclinical hypothyroid groups 
 
Table 2. Prevalence of hypothyroid symptoms and risk factors for subclinical 
hypothyroidism   
 
Figure 3. Total number of hyperthyroid symptoms reported by the euthyroid and 
subclinical hyperthyroid groups 
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Table 1. Classification of thyroid status based upon TSH and FT4 concentration  




thyroxine (FT4)  
pmol/L 
Overt hyperthyroidism <0.30 >10 
Subclinical hyperthyroidism  < 0.30 10-22 
Euthyroid  0.3  4.5 10-22 
Subclinical hypothyroidism >4.50 10-22 







Table 2. Prevalence of hypothyroid symptoms and risk factors for subclinical 
hypothyroidism   
Symptoms  Euthyroid 
n=2703 




% (95% CI) 
Unadjusted  
OR (95% CI) 
p value 
Adjusted  
ORa (95% CI) 
p value 
 
9 symptoms typically associated with overt hypothyroidism 




































3 symptoms which can be associated with overt hyper or hypothyroidism 












Multiple symptoms   
Total number of 










a adjusted odds of subclinical hypothyroidism after controlling for sociodemographic factors (age, gender, 
deprivation score, smoking status) and concomitant disease and prescription medication. 















% (95% CI) 
Unadjusted  
OR (95% CI) 
p value 
Adjusted  
ORa (95% CI) 
p value 
6 symptoms typically associated with hyperthyroidism  
























3 symptoms which can be associated with overt hyper or hypothyroidism  












Multiple symptoms  
Total number of 










a  adjusted odds of subclinical hyperthyroidism after controlling for sociodemographic factors (age, gender, 
deprivation score, smoking status) and concomitant disease and prescription medication.  
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treated for 
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full screen   





2703 (94%)  
euthyroid 
138 (5%) 
subclinical 
hypothyroidism  
 
15 
 
 
 
 
 
 
16 
 
 
 
 
 
 
 
 
